Time New York: Thu 19 Oct 18:03 pm  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

Ashland to Refinance Senior Notes Due 2018 with New Facility

Zacks

Ashland Global Holdings Inc. ASH said that its fully-owned subsidiary Ashland LLC, is planning to refinance its 3.875% senior notes due 2018. The company is looking for obtaining fresh senior secured term loan B facility of around $600 million to retire the senior notes.

Ashland also plans to refinance the existing $800 million unsecured senior revolving credit facility with a 5-year secured senior revolving credit facility of the same amount. The company is also considering a fresh $250 million 3-year and $250 million 5-year, senior secured term loan A facilities. This will be used to finance part of consideration for pending acquisition of Pharmachem Laboratories, Inc., that was previously announced by the company.

Ashland reported a net income from continuing operations of $102 million or $1.42 per share in the second quarter of fiscal 2017, compared to net income of $87 million or $1.38 in the year-ago period.

Barring one-time items, adjusted earnings were $1.71 per share, down 6.6% year over year. However, earnings beat the Zacks Consensus Estimate of $1.61.

Ashland Global Holdings Inc. Price and Consensus

Ashland Global Holdings Inc. Price and Consensus | Ashland Global Holdings Inc. Quote


Revenues increased 5.8% year over year to $1,320 million, topping the Zacks Consensus Estimate of $1,283 million. The company gained from price improvements and cost management strategies, partly offsetting the adverse impacts of foreign currency translation and higher-than-expected cost of raw materials.

According to the Chairman and CEO, William A. Wulfsohn, the company witnessed year-over-year growth in sales and volume of Specialty Ingredients as well as sales growth of Performance Materials and volume growth in Composites segments. The acquisition of Pharmachem, which is leading player in the global health and wellness industry is expected to be completed by the end of Jun 2017. The buyout will strengthen Ashland’s specialty portfolio segment in the high-margin end markets, boost its foothold in fast-growing nutraceutical end markets and also open new opportunities within flavors and fragrances.

However, increasing raw material costs and a strong dollar in the second quarter acted as deterrents. To minimize the combined impact of incremental expense, the Ashland Specialty Ingredient (ASI) team is working to reduce costs and implement price increase.

Ashland’s another priority is to become a leading specialty chemical company by capitalizing on the highly differentiated portfolio, driving strong cash conversion and deliver top-quartile growth and margin. The proposed acquisition of Pharmachem is in sync with this strategy.

Ashland’s shares have declined 48.4% in the last three months, underperforming the Zacks categorized Chemical-Specialty industry’s gain of 1.6%.



Ashland currently carries a Zacks Rank #3 (Hold).

Stocks to Consider

Better-ranked companies in the basic materials space include Kronos Worldwide Inc KRO, Methanex Corporation MEOH and ArcelorMittal MT. All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.

Kronos has an expected long-term earnings growth of 5%.

Methanex has an expected long-term earnings growth of 15%.

ArcelorMittal has an expected long-term earnings growth of 11.5%.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.